NCT06123780 is a clinical trial in Acute Exacerbation COPD, sponsored by Assiut University.

Who is sponsoring NCT06123780?

NCT06123780 is sponsored by Assiut University.

What condition does NCT06123780 study?

NCT06123780 studies Acute Exacerbation COPD.

Is NCT06123780 still recruiting?

NCT06123780 is currently status unknown. Last updated 22 November 2023.

Last reviewed 2023-11-22 · How we verify

NCT06123780

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pattern of Microbial Infection in AECOPD Patients and Its Sensitivity to Antibiotics

Status unknown Last updated 22 November 2023

What this trial tests

trial in Acute Exacerbation COPD in 140 participants. Status unknown.

Timeline

1 December 2023

Primary endpoint
1 November 2024

1 December 2024

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	140
Start date	1 December 2023
Primary completion	1 November 2024
Estimated completion	1 December 2024

Conditions studied

Acute Exacerbation COPD — all drugs for Acute Exacerbation COPD →

Sponsor

Assiut University

Who can join

Adults 18 to 80, any sex, with Acute Exacerbation COPD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Measurement of bacterial species causing AECOPD and their Sensitivity pattern to antibiotics.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06123780 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 22 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06123780.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing